← Eichor
Condition: Hr Positive Breast Cancer Synced from ClinicalTrials.gov · July 30, 2026

Recruiting studies: Hr Positive Breast Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Trial of HRS-6209-205 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Combination T
Phase 1 · 3 location(s) · Atridia Pty Ltd. · NCT07358377A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Phase 2 · 13 location(s) · Processa Pharmaceuticals · NCT06568692First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Parti
Phase 1/Phase 2 · 65 location(s) · Eli Lilly and Company · NCT05768139A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer
Phase 1 · 2 location(s) · Shanghai Best-Link Bioscience, LLC · NCT06738966BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Phase 1 · 63 location(s) · BeOne Medicines · NCT06120283Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
Phase 1/Phase 2 · 2 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT04923542VS-6766+Abema+Fulv in Met HR+/HER- BC
Phase 1/Phase 2 · 3 location(s) · Adrienne G. Waks · NCT05608252Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced
Phase 2 · 2 location(s) · wanghaibo · NCT07285382Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT05985655DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients
Phase N/A · 1 location(s) · Mayo Clinic · NCT06388122Role of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2
Phase N/A · 1 location(s) · University Hospital, Basel, Switzerland · NCT07546695Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-ca
Phase 3 · 7 location(s) · West German Study Group · NCT07281833Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormon
Phase N/A · 24 location(s) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT06805812A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Phase 3 · 52 location(s) · Genor Biopharma Co., Ltd. · NCT05851014Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer
Phase 2 · 11 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT04965766A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Ca
Phase 2 · 1 location(s) · Fudan University · NCT07666555Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer
Phase 1/Phase 2 · 1 location(s) · Nagoya City University · NCT07164976Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
NA · 39 location(s) · Natera, Inc. · NCT07214532A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
Phase 1 · 18 location(s) · Totus Medicines · NCT05683418Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks
Phase 3 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT05212454ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness
NA · 14 location(s) · Austrian Breast & Colorectal Cancer Study Group · NCT07084558Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 N
Phase 2 · 13 location(s) · TransThera Sciences (Nanjing), Inc. · NCT07498478NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.
Phase N/A · 1 location(s) · Henan Cancer Hospital · NCT06781281A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Meta
Phase 2 · 53 location(s) · Puma Biotechnology, Inc. · NCT06369285To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
Phase 2 · 30 location(s) · Hoffmann-La Roche · NCT07368998Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Canc
Phase 1/Phase 2 · 7 location(s) · Faeth Therapeutics · NCT07558733Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Recepto
Phase N/A · 40 location(s) · Novartis Pharmaceuticals · NCT06930859Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 · 40 location(s) · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · NCT06625775Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
Phase 1 · 3 location(s) · Novartis Pharmaceuticals · NCT07604571Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for
NA · 1 location(s) · Medical College of Wisconsin · NCT06106477
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.